预测索拉非尼治疗晚期肝细胞肝癌疗效的生物标志物研究进展

发布时间：2018-06-09 13:44

本文选题：癌 + 肝细胞　；参考：《肿瘤》2017年10期

【摘要】：肝细胞肝癌(hepatocellular carcinoma,HCC)是人类常见的恶性肿瘤,在所有恶性肿瘤中其死亡率位居第3位。目前,索拉非尼是晚期HCC唯一批准上市的分子靶向治疗药物。然而,索拉非尼在晚期HCC中的治疗效果并不理想,存在较大的个体差异。为了优化晚期HCC患者的治疗方案,减少医疗支出,改善患者的生活质量,人们对预测索拉非尼治疗晚期HCC疗效生物标志物的研究越来越重视。研究表明,肿瘤组织中磷酸化细胞外调节蛋白激酶(phosphorylated extracellular signal regulated kinase,p ERK)、c-Jun氨基末端激酶(c-Jun N-terminal kinase,JNK)信号通路下游的c-Jun磷酸化水平和血管内皮生长因子受体2(vascular endothelial growth factor receptor-2,VEGFR-2)的表达水平,血清中甲胎蛋白(alpha-fetoprotein,AFP)、转化生长因子(transforming growth factor,TGF)和血管内皮生长因子(vascular endothelial growth factor,VEGF)的浓度,以及循环肿瘤细胞中p ERK和磷酸化蛋白激酶B(protein kinase B,PKB,又称Akt)的表达,是预测索拉非尼疗效的重要因素,具有作为新的生物标志物的应用前景。本文对近年来的相关临床队列研究进行综述。
[Abstract]:Hepatocellular carcinoma (HCC) is a common malignant tumor in human, and its mortality rate ranks third among all malignant tumors. Currently, sorafenib is the only molecular targeted therapy approved for advanced HCC. However, the efficacy of Solafenib in the treatment of advanced HCC is not satisfactory, and there are significant individual differences. In order to optimize the treatment plan of advanced HCC patients, reduce medical expenses, improve the quality of life of patients, people pay more and more attention to the biomarkers of predicting the efficacy of Solafenil in the treatment of advanced HCC. The results showed that phosphorylated extracellular signal regulated kinase phosphorylated protein kinase phosphorylation and expression of vascular endothelial growth factor receptor 2(vascular endothelial growth factor receptor 2 (VEGFR-2) downstream of c-Jun N-terminal kinase signaling pathway. Serum levels of alpha-fetoprotein (growth), transforming growth factor (growth) and vascular endothelial growth factor (endothelial growth), and the expression of pERK and phosphorylated protein kinase (PKB) in circulating tumor cells. It is an important factor to predict the curative effect of Solafenib and has the prospect of application as a new biomarker. This article reviews the clinical cohort studies in recent years.
【作者单位】：复旦大学附属中山医院肝癌研究所;复旦大学上海医学院;
【分类号】：R735.7

【相似文献】